Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17866480 | 1.00 | CA1 (0.37) | CA1CA9CA2CA4KMT2A | |
| SCHEMBL2127362 | 0.91 | CA1 (0.42) | CA1CA9CA2CA4KMT2A | |
| SCHEMBL4353566 | 0.91 | CA1 (0.42) | CA1CA9CA2CA4KMT2A | |
| SCHEMBL7808875 | 0.89 | CA1 (0.41) | CA1CA9CA2CA4KMT2A | |
| SCHEMBL8749849 | 0.88 | CA1 (0.53) | CA1CA9TSHRCYP2D6 | |
| SCHEMBL1491997 | 0.86 | CA1 (0.44) | CA1CA9CA2CA4KMT2A | |
| SCHEMBL4938203 | 0.85 | CA1 (0.32) | CA1CA9 | |
| SCHEMBL5880374 | 0.79 | CA1 (0.46) | CA1CA9TSHRCYP2D6 | |
| SCHEMBL3138434 | 0.78 | CA1 (0.37) | CA1CA9CA2CA4KMT2A | |
| SCHEMBL1329704 | 0.78 | CA1 (0.37) | CA1CA9CA2CA4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621656-B1 | OCULAR DRUG DELIVERY FORMULATION | INMED PHARMACEUTICALS INC (CA) | 2023-11-29 | — | — | EP | claimed |
| CN-113301884-A | Non-aqueous chemotherapy oral suspensions | 夫特弗制药私人有限公司 | 2021-08-24 | — | — | CN | claimed |
| US-20200163900-A1 | OCULAR DRUG DELIVERY FORMULATION | INMED PHARMACEUTICALS INC. (CA) | 2020-05-28 | — | — | US | claimed |
| US-20170209375-A1 | NANOPARTICLE FORMULATIONS OF LOW-WATER SOLUBILITY ACTIVES | BEND RESEARCH, INC. (US) | 2017-07-27 | — | — | US | claimed |
| EP-2162120-B1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | BEND RES INC (US) | 2016-05-04 | — | — | EP | claimed |
| US-8974827-B2 | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer | BEND RESEARCH, INC. (US) | 2015-03-10 | — | — | US | claimed |
| EP-2653867-A1 | Biotracer and its use in an immunoassay | King Saud University (SA) | 2013-10-23 | — | — | EP | claimed |
| US-20100323014-A1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | PFIZER INC. | 2010-12-23 | — | — | US | claimed |
| EP-2162120-A2 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | Bend Research, Inc (US) | 2010-03-17 | — | — | EP | claimed |
| WO-2008149192-A2 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | PFIZER PRODUCTS INC. (US) | 2008-12-11 | — | — | WO | claimed |
| US-11835526-B2 | Functionalized chromophoric polymer dots and bioconjugates thereof | UNIVERSITY OF WASHINGTON (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3621656-B1 | OCULAR DRUG DELIVERY FORMULATION | INMED PHARMACEUTICALS INC (CA) | 2023-11-29 | — | — | EP | disclosed |
| US-11585818-B2 | Chromophoric polymer dots | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2023-02-21 | — | — | US | disclosed |
| CN-112079984-B | Thermoplastic polyurethane block copolymer, block copolymer film and preparation method thereof | 浙江华峰热塑性聚氨酯有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-11249086-B2 | Functionalized chromophoric polymer dots and bioconjugates thereof | UNIVERSITY OF WASHINGTON (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2005065081-A2 | BIOCONJUGATED NANOSTRUCTURES, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | EMORY UNIVERSITY (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050136258-A1 | Nanoparticle fluorescent probes comprised of quantum dot and hydrophobic protection structure including capping ligand and amphiphilic copolymer; biocompatibility; multiplexed imaging and detection of genes and proteins in single living cells; cancer diagnosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005007136-A1 | METHODS OF MAKING PHARMACEUTICAL FORMULATIONS FOR THE DELIVERY OF DRUGS HAVING LOW AQUEOUS SOLUBILITY | IMARX THERAPEUTICS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040247624-A1 | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility | IMARX THERAPEUTICS, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040126900-A1 | High affinity peptide- containing nanoparticles | ALNIS BIOSCIENCES INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323014-A1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | LRBA, CEL, TNNC1 | CA1 1596/4885CA9 210/4885CA2 363/4885 |
| US-20170209375-A1 | NANOPARTICLE FORMULATIONS OF LOW-WATER SOLUBILITY ACTIVES | ACP1, AQP1, AQP3 | CA1 135/4885CA9 359/4885CA2 718/4885 |
| US-20040126900-A1 | High affinity peptide- containing nanoparticles | LNPEP, IAPP, ACP1 | CA1 1783/4885CA9 2286/4885CA2 3442/4885 |
| US-20040247624-A1 | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility | ACR, LPXN, ABCG2 | CA1 1049/4885CA9 1323/4885CA2 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.